Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2012 Feb;138(2):221-9.
doi: 10.1007/s00432-011-1091-0. Epub 2011 Nov 18.

Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer

Maurizio Belfiglio  1 , Caterina Fanizza, Nicola Tinari, Corrado Ficorella, Stefano Iacobelli, Clara Natoli; Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO)
Affiliations
Meta-Analysis

Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer

Maurizio Belfiglio et al. J Cancer Res Clin Oncol. 2012 Feb.

Abstract

Purpose: Whether combination chemotherapy offers an advantage over sequential therapy in metastatic breast cancer (MBC) is still an unsettled issue. Polychemotherapy regimens containing taxanes has been shown to increase overall survival (OS), time to tumor progression (TTP), and overall response rate (ORR) when compared with regimens that did not contain a taxanes, while taxane-based doublets have a statistically significant benefit over single-agent taxane only for progression-free survival. However, the term "taxanes" generally includes both paclitaxel and docetaxel, drugs with different clinical activity. Aim of this work is to compare OS, TTP, and ORR in patients with MBC receiving docetaxel alone or in combination with chemotherapy using a formal meta-analysis.

Methods: We performed a systematic review of all published trials comparing docetaxel alone or in combination with other chemotherapeutic agents in MBC.

Results: Three randomized clinical trials including 1,313 patients were retrieved. A significant reduction of risk ratio was found in TTP (P ≤ 0.0001) but not in OS (P = 0.48) or ORR (P = 0.10) for patients treated with a chemotherapy agent plus docetaxel compared with docetaxel alone. Treatment with docetaxel alone is associated with a lower incidence of grade 3 diarrhea and stomatitis (diarrhea, P = 0.011; stomatitis, P = 0.0004).

Conclusion: Combination chemotherapy regimens with docetaxel show a statistically significant advantage for TTP, but not for OS and ORR in MBC. This review confirms that it is unlikely that any single agent or combination chemotherapy regimen will emerge as superior in MBC, due to its heterogeneous nature.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overall survival and time to tumor progression risk ratios
Fig. 2
Fig. 2
Overall response rate risk ratios
Fig. 3
Fig. 3
G3 and G4 toxicity risk ratio
See this image and copyright information in PMC

References

    1. Ardavanis A, Kountourakis P, Kyriakou F, Malliou S, Mantzaris I, Garoufali A, Yiotis I, Scorilas A, Baziotis N, Rigatos G (2008) Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. Oncologist 13(4):361–369. doi:10.1634/theoncologist.2007-0207 - DOI - PubMed
    1. Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Kostler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H (2009) Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 20(11):1771–1785. doi:10.1093/annonc/mdp261 - DOI - PubMed
    1. Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, Esteva FJ (2008) Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100(16):1179–1183. doi:10.1093/jnci/djn233 - DOI - PMC - PubMed
    1. Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP (2007) Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 110(5):965–972. doi:10.1002/cncr.22885 - DOI - PubMed
    1. Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Luck HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, Therasse P (2008) Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26(12):1987–1992. doi:10.1200/jco.2007.10.8407 - DOI - PubMed

MeSH terms